Ardent Health (NYSE:ARDT) Updates FY 2026 Earnings Guidance

04 Mar 2026, 17:14 by Renee Jackson · The Cerbat Gem

Ardent Health (NYSE:ARDT – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.900-1.270 for the period, compared to the consensus earnings per share estimate of 1.400. The company issued revenue guidance of $6.4 billion-$6.7 billion, compared to the consensus revenue estimate of $6.7 billion.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Truist Financial reduced their price target on Ardent Health from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Guggenheim reduced their target price on shares of Ardent Health from $18.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. UBS Group lowered their price target on shares of Ardent Health from $14.50 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Leerink Partners set a $16.00 price target on shares of Ardent Health in a research report on Friday, November 14th. Finally, KeyCorp cut Ardent Health from an “overweight” rating to a “sector weight” rating in a report on Monday, November 17th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Ardent Health has an average rating of “Hold” and an average target price of $14.58.

Get Our Latest Research Report on ARDT

Ardent Health Stock Performance

Shares of ARDT traded up $0.18 during midday trading on Wednesday, reaching $9.59. The stock had a trading volume of 368,054 shares, compared to its average volume of 401,265. The firm has a market cap of $1.37 billion, a PE ratio of 6.61, a P/E/G ratio of 5.22 and a beta of 0.46. The firm has a 50 day simple moving average of $8.98 and a 200-day simple moving average of $11.05. Ardent Health has a one year low of $8.07 and a one year high of $15.48. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Ardent Health (NYSE:ARDT – Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.03). Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.63 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. As a group, sell-side analysts anticipate that Ardent Health will post 1.23 EPS for the current year.

Ardent Health News Roundup

Here are the key news stories impacting Ardent Health this week:

Positive Sentiment: Ardent confirmed it will participate in March investor conferences — a chance for management to engage with investors and address the receivables/accounting issues directly, which could help calm markets if management provides clear updates. Ardent Health to Participate in March Investor Conferences
Neutral Sentiment: One firm (Faruqi & Faruqi) cited a later April 21, 2026 deadline for lead‑plaintiff applications — a different date than many other notices — which may prolong headline risk and create scheduling/coordination uncertainty for potential plaintiffs. ARDT SHAREHOLDER REMINDER
Negative Sentiment: Multiple national law firms (Hagens Berman, RGRD, Bronstein Gewirtz, Levi & Korsinsky, Rosen, Kahn Swick & Foti, Bleichmar Fonti & Auld, others) are actively soliciting Ardent investors to join or lead a securities class action tied to disclosures covering July 18, 2024–Nov 12, 2025; that cascade of notices increases litigation risk and ongoing headline pressure. MONDAY DEADLINE: Ardent Health, Inc. Investors…
Negative Sentiment: Hagens Berman and others point to an alleged ~$97M “accounting shock” tied to Ardent’s use of a rigid “180‑day cliff” to reserve for uncollectible accounts — an approach the complaints say contradicts prior statements about detailed historical collection reviews. That specific allegation is the core catalyst for the prior ~33% stock drop and could lead to financial restatements, reserves, or regulatory scrutiny. ARDT WRITE OFFS: Hagens Berman Investigating Claims…

Hedge Funds Weigh In On Ardent Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARDT. Invesco Ltd. increased its holdings in shares of Ardent Health by 24.4% in the fourth quarter. Invesco Ltd. now owns 71,304 shares of the company’s stock valued at $630,000 after purchasing an additional 13,964 shares during the last quarter. Empowered Funds LLC boosted its stake in Ardent Health by 135.0% in the 4th quarter. Empowered Funds LLC now owns 551,738 shares of the company’s stock valued at $4,872,000 after purchasing an additional 316,961 shares during the period. VARCOV Co. acquired a new position in Ardent Health in the 4th quarter valued at $232,000. Susquehanna Portfolio Strategies LLC grew its stake in shares of Ardent Health by 101.8% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 62,957 shares of the company’s stock valued at $556,000 after acquiring an additional 31,758 shares in the last quarter. Finally, Numerai GP LLC acquired a new position in shares of Ardent Health during the 4th quarter worth approximately $616,000.

About Ardent Health

(Get Free Report)

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.